Fortrea boosts early-phase CRO platform with $45M acquisition of Worldwide division September 2, 2026Posted inResearch Fortrea has agreed to acquire the early-phase services division of fellow CRO Worldwide Clinical Trials for $45 million. Post navigation Previous Post Teva autoimmune antibody notches ph. 2 win in celiac diseaseNext PostBuilding the Data Foundation for AI-Driven Clinical Development
